Patents by Inventor Vincent Vieillard

Vincent Vieillard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions for preventing and/or treating an infection by an HIV-1 virus
    Patent number: 10174080
    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein Nt consists of a peptide having from 0 to 50 amino acids in length, Ct consists of a peptide having from 0 to 50 amino acids in length, each of X1 to X4 consists of an amino acid residue, wherein: (i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, (i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, (i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, (i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meani
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: January 8, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), INNAVIRVAX
    Inventors: Patrice Debre, Vincent Vieillard
  • COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS
    Publication number: 20180057535
    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID N° 1], wherein Nt consists of a peptide having from 0 to 50 amino acids in length, Ct consists of a peptide having from 0 to 50 amino acids in length, each of X1 to X4 consists of an amino acid residue, wherein: (i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, (i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, (i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, (i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meani
    Type: Application
    Filed: September 22, 2017
    Publication date: March 1, 2018
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), INNAVIRVAX
    Inventors: Patrice DEBRE, Vincent VIEILLARD
  • Compositions for preventing and/or treating an infection by an HIV-1 virus
    Patent number: 9802983
    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein —Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that —three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and —the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: October 31, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MEDICALÉ (INSERM), INNAVIRVAX
    Inventors: Patrice Debre, Vincent Vieillard
  • POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
    Publication number: 20170128564
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
    Type: Application
    Filed: November 23, 2016
    Publication date: May 11, 2017
    Inventors: Vincent VIEILLARD, Patrice DEBRE
  • COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS
    Publication number: 20160031943
    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein —Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that —three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and —the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in
    Type: Application
    Filed: September 30, 2015
    Publication date: February 4, 2016
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), INNAVIRVAX
    Inventors: Patrice DEBRE, Vincent VIEILLARD
  • Compositions for detecting an infection by an HIV-1 virus
    Patent number: 9181299
    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein—Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that—three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and—the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: November 10, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Innavirvax
    Inventors: Patrice Debre, Vincent Vieillard
  • POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
    Publication number: 20140335119
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 13, 2014
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique Hopitaux de Paris
    Inventors: Vincent VIEILLARD, Patrice DEBRE
  • COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS
    Publication number: 20140037666
    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S—X1-X2-X3-K—X4-Ct (I) [SEQ ID No 1], wherein—Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that—three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and—the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its
    Type: Application
    Filed: April 13, 2012
    Publication date: February 6, 2014
    Applicant: INNAVIRVAX
    Inventors: Patrice Debre, Vincent Vieillard
  • POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
    Publication number: 20090136533
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
    Type: Application
    Filed: January 29, 2009
    Publication date: May 28, 2009
    Applicants: INSERM (Institut National de la Recherche Medicale), Assistance Publique Hopitaux de Paris
    Inventors: Vincent Vieillard, Patrice Debre
  • Method for the In Vitro Assessment of the Progression Status of an Infection by an HIV Virus in an Individual
    Publication number: 20090117110
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.
    Type: Application
    Filed: October 29, 2007
    Publication date: May 7, 2009
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ( INSERM), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Vincent Vieillard, Patrice Debre
  • Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
    Publication number: 20070092525
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
    Type: Application
    Filed: February 7, 2005
    Publication date: April 26, 2007
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique Hopitaux de Paris
    Inventors: Vincent Vieillard, Patrice Debre
  • Method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual
    Publication number: 20060257318
    Abstract: The present invention relates to the field of the in vitro diagnosis nosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.
    Type: Application
    Filed: February 6, 2004
    Publication date: November 16, 2006
    Applicants: Institut National de la Sante et de la Recherche M, Assistance Publique Hopitaux de Paris
    Inventors: Vincent Vieillard, Patrice Debre